170 related articles for article (PubMed ID: 30848067)
1. Use of granulocyte colony-stimulating factor and risk of relapse in pediatric patients treated for acute myeloid leukemia according to NOPHO-AML 2004 and DB AML-01.
Løhmann DJA; Asdahl PH; Abrahamsson J; Ha SY; Jónsson ÓG; Kaspers GJL; Koskenvuo M; Lausen B; De Moerloose B; Palle J; Zeller B; Hasle H
Pediatr Blood Cancer; 2019 Jun; 66(6):e27701. PubMed ID: 30848067
[TBL] [Abstract][Full Text] [Related]
2. Impact on acute myeloid leukemia relapse in granulocyte colony-stimulating factor application: a meta-analysis.
Feng X; Lan H; Ruan Y; Li C
Hematology; 2018 Oct; 23(9):581-589. PubMed ID: 29516766
[TBL] [Abstract][Full Text] [Related]
3. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
4. Effects of priming with recombinant human granulocyte colony-stimulating factor on conditioning regimen for high-risk acute myeloid leukemia patients undergoing human leukocyte antigen-haploidentical hematopoietic stem cell transplantation: a multicenter randomized controlled study in southwest China.
Gao L; Wen Q; Chen X; Liu Y; Zhang C; Gao L; Kong P; Zhang Y; Li Y; Liu J; Wang Q; Su Y; Wang C; Wang S; Zeng Y; Sun A; Du X; Zeng D; Liu H; Peng X; Zhang X
Biol Blood Marrow Transplant; 2014 Dec; 20(12):1932-9. PubMed ID: 25109850
[TBL] [Abstract][Full Text] [Related]
5. Associations between neutrophil recovery time, infections and relapse in pediatric acute myeloid leukemia.
Løhmann DJA; Asdahl PH; Abrahamsson J; Ha SY; Jónsson ÓG; Kaspers GJL; Koskenvuo M; Lausen B; De Moerloose B; Palle J; Zeller B; Hasle H
Pediatr Blood Cancer; 2018 Sep; 65(9):e27231. PubMed ID: 29781563
[TBL] [Abstract][Full Text] [Related]
6. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia.
Löwenberg B; van Putten W; Theobald M; Gmür J; Verdonck L; Sonneveld P; Fey M; Schouten H; de Greef G; Ferrant A; Kovacsovics T; Gratwohl A; Daenen S; Huijgens P; Boogaerts M; ;
N Engl J Med; 2003 Aug; 349(8):743-52. PubMed ID: 12930926
[TBL] [Abstract][Full Text] [Related]
7. Fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin for relapsed childhood acute myeloid leukemia.
Nakayama H; Tomizawa D; Tanaka S; Iwamoto S; Shimada A; Saito AM; Yamashita Y; Moritake H; Terui K; Taga T; Matsuo H; Kosaka Y; Koh K; Hosoi H; Kurosawa H; Isoyama K; Horibe K; Mizutani S; Adachi S
Pediatr Int; 2017 Oct; 59(10):1046-1052. PubMed ID: 28771903
[TBL] [Abstract][Full Text] [Related]
8. Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial.
Gao L; Zhang Y; Wang S; Kong P; Su Y; Hu J; Jiang M; Bai H; Lang T; Wang J; Liu L; Yang T; Huang X; Liu F; Lou S; Liu Y; Zhang C; Liu H; Gao L; Liu J; Zhu L; Wen Q; Chen T; Wang P; Rao J; Mao M; Wang C; Duan X; Luo L; Peng X; Cassady K; Zhong JF; Zhang X
J Clin Oncol; 2020 Dec; 38(36):4249-4259. PubMed ID: 33108244
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial of 2 dosages of prophylactic granulocyte-colony-stimulating factor after induction chemotherapy in pediatric acute myeloid leukemia.
Inaba H; Cao X; Pounds S; Pui CH; Rubnitz JE; Ribeiro RC; Razzouk BI
Cancer; 2011 Mar; 117(6):1313-20. PubMed ID: 21381017
[TBL] [Abstract][Full Text] [Related]
10. Response-guided chemotherapy for pediatric acute myeloid leukemia without hematopoietic stem cell transplantation in first complete remission: Results from protocol DB AML-01.
De Moerloose B; Reedijk A; de Bock GH; Lammens T; de Haas V; Denys B; Dedeken L; van den Heuvel-Eibrink MM; Te Loo M; Uyttebroeck A; Van Damme A; Van der Werff-Ten Bosch J; Zsiros J; Kaspers G; de Bont E
Pediatr Blood Cancer; 2019 May; 66(5):e27605. PubMed ID: 30623572
[TBL] [Abstract][Full Text] [Related]
11. [The potential prognostic influence of granulocyte-colony stimulating factor in acute leukemia].
Liu XM; Chen YZ; Huang MJ; Liu X; Guo JR
Zhonghua Nei Ke Za Zhi; 2005 Jul; 44(7):518-21. PubMed ID: 16080844
[TBL] [Abstract][Full Text] [Related]
12. Granulocyte colony-stimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapse.
Ehlers S; Herbst C; Zimmermann M; Scharn N; Germeshausen M; von Neuhoff N; Zwaan CM; Reinhardt K; Hollink IH; Klusmann JH; Lehrnbecher T; Roettgers S; Stary J; Dworzak M; Welte K; Creutzig U; Reinhardt D
J Clin Oncol; 2010 May; 28(15):2591-7. PubMed ID: 20406937
[TBL] [Abstract][Full Text] [Related]
13. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
Creutzig U; Zimmermann M; Lehrnbecher T; Graf N; Hermann J; Niemeyer CM; Reiter A; Ritter J; Dworzak M; Stary J; Reinhardt D
J Clin Oncol; 2006 Sep; 24(27):4499-506. PubMed ID: 16983120
[TBL] [Abstract][Full Text] [Related]
14. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
[TBL] [Abstract][Full Text] [Related]
15. [A clinical trial for homoharringtonine and low-dose cytosine arabinoside combined with G-CSF or GM-CSF to treat the relapsed or refractory acute myeloid leukemia (AML), geriatric AML and advanced myelodysplastic syndromes].
Xu J; Xu CG; Liu T; Xiang B; Chang H; He C
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Jan; 40(1):129-32. PubMed ID: 19292062
[TBL] [Abstract][Full Text] [Related]
16. Granulocyte colony stimulating factor priming chemotherapy is more effective than standard chemotherapy as salvage therapy in relapsed acute myeloid leukemia.
Shen Y; He A; Wang F; Bai J; Wang J; Zhao W; Zhang W; Cao X; Chen Y; Liu J; Ma X; Chen H; Feng Y; Yang Y
Med Clin (Barc); 2018 Nov; 151(9):339-344. PubMed ID: 29292108
[TBL] [Abstract][Full Text] [Related]
17. Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): estimates from a Southwest Oncology Group clinical trial.
Bennett CL; Hynes D; Godwin J; Stinson TJ; Golub RM; Appelbaum FR;
Cancer Invest; 2001; 19(6):603-10. PubMed ID: 11486703
[TBL] [Abstract][Full Text] [Related]
18. Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer.
Calip GS; Malmgren JA; Lee WJ; Schwartz SM; Kaplan HG
Breast Cancer Res Treat; 2015 Nov; 154(1):133-43. PubMed ID: 26450505
[TBL] [Abstract][Full Text] [Related]
19. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
[TBL] [Abstract][Full Text] [Related]
20. Prolonged granulocyte colony stimulating factor use in glycogen storage disease type 1b associated with acute myeloid leukemia and with shortened telomere length.
Li AM; Thyagu S; Maze D; Schreiber R; Sirrs S; Stockler-Ipsiroglu S; Sutherland H; Vercauteren S; Schultz KR
Pediatr Hematol Oncol; 2018 Feb; 35(1):45-51. PubMed ID: 29652549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]